PASCAL J GOLDSCHMIDT, MD
Osteopathic Medicine at 12 Ave, Miami, FL

2011007, Mar 24, 2011

Aug 19, 2010

12/806690

Jeffery M. Vance - Chapel Hill NC, US
Pascal Goldschmidt - Miami FL, US
Elizabeth Hauser - Durham NC, US
William Kraus - Hillsborough NC, US

C12Q 1/68, C12Q 1/02, C12Q 1/60

435 6, 435 29, 435 11

The LSAMP gene can be used for cardiovascular disease risk assessment, in particular Left Main Disease. The genetic risk attributable to LSAMP adds to known cardiovascular disease risk factors. Assessment of risk attributable to LSAMP permits early initiation of preventive and therapeutic strategies. Given the pronounced clinical risk associated with Left Main Disease, such risk assessment should significantly reduce morbidity and mortality.

2009022, Sep 10, 2009

Nov 10, 2006

12/084759

Elizabeth Hauser - Durham NC, US
Pascal Goldschmidt - Miami FL, US
Simon Gregory - Durham NC, US
William Kraus - Hillsborough NC, US
Jeffery Vance - Coral Gables FL, US

C12Q 1/68, A61K 39/395, A61P 9/00

4241301, 435 6

The invention relates to predicting, or aiding in predicting, which individuals are at risk of developing coronary artery disease. The invention provides a method for identifying an individual who has an altered risk for developing CAD. The invention further relates to methods of reducing the likelihood that a subject will develop CAD. The invention further provides reagents, nucleic acids and kits comprising nucleic acids containing a polymorphism in a CAD-determinative gene.

2009008, Apr 2, 2009

Feb 14, 2008

12/031528

Jeffery M. Vance - Coral Gables FL, US
Pascal J. Goldschmidt - Miami FL, US
Simon G. Gregory - Durham NC, US
William E. Kraus - Hillsborough NC, US
Elizabeth R. Hauser - Durham NC, US

C12Q 1/68

435 6

The present invention provides methods of identifying a subject having an increased or decreased risk of developing cardiovascular disease, comprising:

2007014, Jun 28, 2007

Jul 18, 2006

11/458228

Jeffery Vance - Chapel Hill NC, US
Pascal Goldschmidt - Miami FL, US
Elizabeth Hauser - Durham NC, US
William Kraus - Hillsborough NC, US

Duke University - Durham NC

C12Q 1/68, G06F 19/00

435006000, 702020000

The LSAMP gene can be used for cardiovascular disease risk assessment, in particular Left Main Disease. The genetic risk attributable to LSAMP adds to known cardiovascular disease risk factors. Assessment of risk attributable to LSAMP permits early initiation of preventive and therapeutic strategies. Given the pronounced clinical risk associated with Left Main Disease, such risk assessment should significantly reduce morbidity and mortality.

2011028, Nov 24, 2011

Oct 14, 2009

13/124220

David M. Seo - Pinecrest FL, US
Pascal J. Goldschmidt - Miami FL, US
Jennifer Clarke - Miami FL, US

University of Miami - Miami FL

C40B 30/04, C40B 40/06

506 9, 506 16

This invention relates, e.g., to a method for screening a subject for the presence of coronary atherosclerosis, said method comprising measuring the expression level of at least 5 of the genes of Table 2 in a biological sample obtained from said subject, wherein an elevated level of expression of said 5 genes compared to a control level measured in a population of normal subjects is indicative of an increased probability of the subject having significant subclinical coronary atherosclerosis. Methods for deciding on a treatment modality, based on a diagnostic procedure of the invention, are also described, as are kits for carrying out a method of the invention.

2008009, Apr 24, 2008

Apr 27, 2007

11/790809

Chunming Dong - Durham NC, US
Pascal Goldschmidt - Miami FL, US

DUKE UNIVERSITY - Durham NC

A61K 35/12, A61P 9/10, C12N 5/06

424093210, 424093700, 435325000, 435366000, 435371000, 435372000

The present invention relates, in general, to atherosclerosis and, in particular, to a method of treating atherosclerosis and to cells suitable for use in such a method.